# Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

> **NCT07262983** · PHASE1 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 20 (estimated)

## Conditions studied

- Hyper IgE Syndrome From STAT3 Mutation
- Job s Syndrome
- HIES
- Lupus
- Atopic Dermatitis

## Interventions

- **DRUG:** baricitinib

## Key facts

- **NCT ID:** NCT07262983
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2030-05-01
- **Final completion:** 2030-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07262983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07262983, "Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07262983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*